Vet Times Podcast

Nerve growth factor (NGF) is a key player in osteoarthritis (OA) pain transmission and, as a result, anti-NGF drugs (monoclonal antibodies bedinvetmab for dogs and frunevetmab for cats) represent a novel therapeutic target for OA. In this episode, Congress Times editor Tom Jackson speaks to Matt Gurney of Anderson Moores Veterinary Specialists about his early experiences of using this treatment, and how the role of NGF – and the drugs that work against it – is an untapped pathway in OA management. _____________________ MATTHEW GURNEY BVSc CertVA PgCertVBM DipECVAA FRCVS Matt graduated from the University of Liverpool in 2003 and spent several years enjoying mixed practice before returning to Liverpool to undertake a residency in anaesthesia and analgesia. From 2009 to 2018 he developed and led the anaesthesia service at Northwest Veterinary Specialists, a multidisciplinary specialist hospital in Cheshire. Matt is a European Veterinary Specialist and an RCVS Recognised Specialist and is currently Presiden